AXIM Biotechnologies, Inc. (AXIM)
OTC Markets OTCID
Price as at 30 Sept 2026, 16:17 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
AXIM Biotechnologies, Inc. trades at $0.00. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About AXIM Biotechnologies, Inc.
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery. In addition, the company develops a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring, as well as COVID-19 rapid diagnostic tools. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its AXIM data?
Fundamentals for AXIM come from company filings and exchange data, as listed on OTC Markets OTCID; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:17 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for AXIM, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.